Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 30.06
(0.2%)
CNY 30.06
(0.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -397.58 Million CNY | -119.23% |
| 2022 | 2.06 Billion CNY | -57.97% |
| 2021 | 4.92 Billion CNY | 193.33% |
| 2020 | 1.67 Billion CNY | 1942.94% |
| 2019 | 82.1 Million CNY | 25.6% |
| 2018 | 65.36 Million CNY | 95.97% |
| 2017 | 33.35 Million CNY | -6.37% |
| 2016 | 35.62 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -67.35 Million CNY | 79.29% |
| 2024 Q3 | -110.54 Million CNY | -31.21% |
| 2024 Q2 | -84.25 Million CNY | -25.09% |
| 2023 Q2 | 85.13 Million CNY | 283.44% |
| 2023 FY | -397.58 Million CNY | -119.23% |
| 2023 Q1 | -46.41 Million CNY | 95.31% |
| 2023 Q3 | -107.19 Million CNY | -225.9% |
| 2023 Q4 | -325.19 Million CNY | -203.38% |
| 2022 Q2 | 674.96 Million CNY | -67.34% |
| 2022 FY | 2.06 Billion CNY | -57.97% |
| 2022 Q4 | -988.92 Million CNY | -419.12% |
| 2022 Q3 | 309.88 Million CNY | -54.09% |
| 2022 Q1 | 2.06 Billion CNY | 106.48% |
| 2021 Q1 | 1.18 Billion CNY | 17.12% |
| 2021 Q3 | 525.01 Million CNY | -76.22% |
| 2021 FY | 4.92 Billion CNY | 193.33% |
| 2021 Q4 | 1 Billion CNY | 90.65% |
| 2021 Q2 | 2.2 Billion CNY | 86.11% |
| 2020 Q3 | 140.5 Million CNY | -70.73% |
| 2020 Q1 | 43.91 Million CNY | 84.89% |
| 2020 FY | 1.67 Billion CNY | 1942.94% |
| 2020 Q4 | 1.01 Billion CNY | 620.88% |
| 2020 Q2 | 480.03 Million CNY | 993.06% |
| 2019 Q3 | 25.13 Million CNY | 19.14% |
| 2019 FY | 82.1 Million CNY | 25.6% |
| 2019 Q4 | 23.75 Million CNY | -5.51% |
| 2019 Q2 | 21.1 Million CNY | 74.18% |
| 2019 Q1 | 12.11 Million CNY | -31.67% |
| 2018 Q4 | 17.72 Million CNY | 0.0% |
| 2018 FY | 65.36 Million CNY | 95.97% |
| 2017 FY | 33.35 Million CNY | -6.37% |
| 2016 FY | 35.62 Million CNY | 0.0% |